| dc.contributor.author | HARDIMAN, ORLA | en |
| dc.date.accessioned | 2018-08-21T14:58:23Z | |
| dc.date.available | 2018-08-21T14:58:23Z | |
| dc.date.issued | 2018 | en |
| dc.date.submitted | 2018 | en |
| dc.identifier.citation | Andrews, J.A. and Cudkowicz, M.E. and Hardiman, O. and Meng, L. and Bian, A. and Lee, J. and Wolff, A.A. and Malik, F.I. and Shefner, J.M., VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 259-266 | en |
| dc.identifier.other | Y | en |
| dc.description | PUBLISHED | en |
| dc.format.extent | 259-266 | en |
| dc.relation.ispartofseries | Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | en |
| dc.rights | Y | en |
| dc.title | VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics | en |
| dc.type | Journal Article | en |
| dc.type.supercollection | scholarly_publications | en |
| dc.type.supercollection | refereed_publications | en |
| dc.identifier.peoplefinderurl | http://people.tcd.ie/hardimao | en |
| dc.identifier.rssinternalid | 184387 | en |
| dc.identifier.doi | http://dx.doi.org/10.1080/21678421.2018.1426770 | en |
| dc.rights.ecaccessrights | openAccess | |
| dc.identifier.orcid_id | 0000-0003-2610-1291 | en |
| dc.identifier.uri | http://hdl.handle.net/2262/83855 | |
